FDA Orange Book
Is there a generic for Cinvanti?
Cinvanti contains aprepitant. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Cinvanti (aprepitant). The Orange Book shows its last listed patent expires September 18, 2035.
Run it in Rivvi
Map Cinvanti and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Cinvanti products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| emulsion, intravenous | 130MG/18ML (7.2MG/ML) | Marketed (Rx) | None | 0 | None |
NDA 209296, held by HERON THERAPEUTICS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Cinvanti patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 9808465 | September 18, 2035 | Method of use | U-2161 | 209296 |
| 10953018 | September 18, 2035 | Method of use | U-2161 | 209296 |
| 9974794 | September 18, 2035 | Drug product | U-2161 | 209296 |
| 9561229 | September 18, 2035 | Drug product | U-2161 | 209296 |
| 10624850 | September 18, 2035 | Method of use | U-2161 | 209296 |
| 12115254 | September 18, 2035 | Drug product | None | 209296 |
| 9974793 | September 18, 2035 | Drug product | None | 209296 |
| 9974742 | September 18, 2035 | Drug product | None | 209296 |
| 12115255 | September 18, 2035 | Drug product | None | 209296 |
| 11173118 | September 18, 2035 | Drug product | None | 209296 |
| 12290520 | September 18, 2035 | Drug product | None | 209296 |
| 10500208 | September 18, 2035 | Drug product | None | 209296 |
| 11744800 | September 18, 2035 | Drug product | None | 209296 |
Cinvanti NDC codes
Questions
Is there a generic for Cinvanti?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Cinvanti (aprepitant). The Orange Book shows its last listed patent expires September 18, 2035.
What is the generic name for Cinvanti?
The active ingredient in Cinvanti is aprepitant, per the FDA Orange Book.
When does the Cinvanti patent expire?
The last patent listed for Cinvanti in the Orange Book expires September 18, 2035. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.